EUVIMEDEUVIMED entdecken
Crossref

The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic

Andrew Hill iD, Mark J Siedner iD, Cassandra Fairhead iD, Francois Venter

Clinical Infectious Diseases · 06.10.2025 · 81 (3) · 547-554

DOI: 10.1093/cid/ciaf115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.04.2025. Verfasst von Andrew Hill und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Epidemics, Anti-HIV Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: International Treatment Preparedness Coalition..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In total, 1.3 million people acquired human immunodeficiency virus (HIV) in 2023, well behind the UNAIDS goal of <370 000 infections by 2025. Novel 6-monthly injectable pre-exposure prophylaxis (PrEP) medication lenacapavir is highly efficacious and could be epidemic-changing. However, without equitable access infection rates will continue. Gilead Sciences, the originator, currently charges over $40 000 per person-year for lenacapavir as HIV treatment, far exceeding PrEP cost-effectiveness thresholds, even in the richest countries. Yet the projected cost of production at scale is <$100 per person-year. Gilead's new voluntary license for lenacapavir prevention and treatment undermines access. Middle-income countries with fast-growing HIV epidemics have been excluded; 23% of new HIV infections occur in these countries. A coordinated response from governments, donors, civil society, and the private sector including Gilead is urgently required to ensure lenacapavir access is wide enough to eliminate HIV transmission worldwide. Unless crucial changes to the current license are made, compulsory licences may be required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisEpidemicsAnti-HIV AgentsLicensureHumansAcetamidesIndazoles

Stichwörter der Autor:innen

HIVlicencepre-exposure prophylaxistransmission

Substanzen

Anti-HIV AgentslenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Cambridge, Massachusetts, USA.
  • Acute Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Wits Ezintsha, University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.

ORCID-Profile: Andrew Hill, Mark J Siedner, Cassandra Fairhead

Förderung

  • International Treatment Preparedness Coalition.

Zitieren

APA

Hill, A., Siedner, M. J., Fairhead, C., & Venter, F. (2025). The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic. Clinical Infectious Diseases, 81(3), 547-554. https://doi.org/10.1093/cid/ciaf115

Vancouver

Hill A, Siedner MJ, Fairhead C, Venter F. The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic. Clinical Infectious Diseases. 2025;81(3):547-554. doi:10.1093/cid/ciaf115

BibTeX
@article{Hill2025,
  author = {Hill, Andrew and Siedner, Mark J and Fairhead, Cassandra and Venter, Francois},
  title = {The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {3},
  pages = {547--554},
  doi = {10.1093/cid/ciaf115}
}
Kostenlos starten →